<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of anti-malarials that may be considered for presumptive or directed* treatment of &lt;em&gt;Plasmodium falciparum&lt;/em&gt; malaria in sub-Saharan refugees after arrival in the United States</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of anti-malarials that may be considered for presumptive or directed* treatment of <em>Plasmodium falciparum</em> malaria in sub-Saharan refugees after arrival in the United States</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing of anti-malarials that may be considered for presumptive or directed* treatment of <em>Plasmodium falciparum</em> malaria in sub-Saharan refugees after arrival in the United States</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Child dosing<br/> <em>children weighing 5 kg to &lt;35 kg</em></td> <td class="subtitle1">Adult dosing<br/> <em>adults and children weighing &gt;35 kg</em></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Presumptive therapy</td> </tr> <tr> <td class="indent1"> <p><strong>Atovaquine-proguanil</strong></p> (adult tab = 250 mg atovaquone/100 mg proguanil; pediatric tab = 62.5 mg atovaquone/25 mg proquanil)</td> <td> <p><strong>5 to 8 kg:</strong> 2 pediatric tablets once a day for three days</p> <p><strong>9 to 10 kg:</strong> 3 pediatric tablets once a day for three days</p> <p><strong>11 to 20 kg:</strong> 1 adult tablets once a day<sup>¶</sup> for three days</p> <p><strong>21 to 30 kg:</strong> 2 adult tablets once a day<sup>¶</sup> for three days</p> <p><strong>31 to 40 kg:</strong> 3 adult tablets once a day<sup>¶</sup> for three days</p> <strong>&gt;40 kg:</strong> 4 adult tablets once a day<sup>¶</sup> three days</td> <td>4 adult tablets once a day<sup>¶</sup> for three days</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine)</strong></td> <td> <p>A six-dose regimen is recommended with 1 to 3 tablets per dose, depending on body weight:</p> <p><strong>5 to &lt;15 kg:</strong> 1 tablet, then 1 tablet after eight hours, then 1 tablet twice daily (morning and evening) on each of the following two days (total course: 12 tablets)</p> <p><strong>15 to &lt;25 kg:</strong> 2 tablets as a single dose, then 2 tablets after eight hours, then 2 tablets twice daily (morning and evening) on each of the following two days (total course: 18 tablets)</p> <strong>25 to &lt;35 kg:</strong> 3 tablets as a single dose, then 3 tablets after eight hours, then 3 tablets twice daily (morning and evening) on each of the following two days (total course: 18 tablets)<sup>Δ</sup></td> <td> <p>A standard three-day treatment schedule with a total of six doses</p> 4 tablets as a single dose, then 4 tablets after eight hours, then 4 tablets twice daily (morning and evening) on each of the following two days (total course: 24 tablets)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alternatives that may be used as directed therapy*</td> </tr> <tr> <td class="indent1">Quinine sulfate</td> <td>30 mg/kg/day divided in three doses for 3 days</td> <td>650 mg every eight hours for 3 days<sup>◊</sup></td> </tr> <tr> <td class="indent1"><strong>plus</strong> clindamycin</td> <td>20 to 40 mg/kg/day in three doses for 7 days</td> <td>900 mg three times a day for 7 days<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>or</strong> doxycycline<sup>§</sup></td> <td>2 mg/kg/day for 7 days</td> <td>100 mg twice a day for 7 days<sup>◊</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Other alternatives</td> </tr> <tr> <td class="indent1">Mefloquine<sup>¥</sup></td> <td><strong>&lt;45 kg:</strong> 15 mg/kg then 10 mg/kg 12 hours later</td> <td>750 mg then 500 mg 12 hours later<sup>◊</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">* Directed therapy refers to treating after <em>P. falciparum</em> malaria has been detected by diagnostic examination in an asymptomatic individual. NOTE: more specific guidance can be found at: http://www.cdc.gov/malaria/diagnosis_treatment/index.html.<br/>¶ May divide the dose and give one-half the dose in the morning and one-half in the evening for better gastrointestinal tolerance.<br/>Δ Should be taken with foods rich in fat such as milk. If vomiting occurs within one hour after taking the medicine, another dose should be taken.<br/><span class="lozenge">◊</span> Do not exceed adult dosing.<br/>§ Not approved for use in children less than eight years.<br/>¥ Should not be given together with quinine or quinidine. Common adverse effects include nausea, vomiting, diarrhea, dizziness, toxic psychosis, and seizures.</div><div class="graphic_reference">Reproduced from: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases. Domestic refugee health guidelines: Malaria. Centers for Disease Control and Prevention, Division of Global Migration and Quarantine 2012. Available at: <a href="https://www.cdc.gov/immigrantrefugeehealth/pdf/malaria-domestic.pdf" target="_blank">http://www.cdc.gov/immigrantrefugeehealth/pdf/malaria-domestic.pdf</a>.</div><div id="graphicVersion">Graphic 96455 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
